CING
What one share of Cingulate holds
Pharmaceutical Preparations
Cingulate’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.28 |
|---|---|
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$2.38 |
| Cash and investments | $2.04 |
| Debt | $0.54 |
| Book value | $1.69 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$2.79 | $0.11 | −$1.52 | — | $1.84 |
| 2022 | — | −$29.35 | $0.25 | −$26.62 | — | $6.44 |
| 2023 | — | −$311.99 | $2.97 | −$202.28 | — | −$70.61 |
| 2024 | — | −$10.86 | $0.14 | −$12.24 | — | — |
| 2025 | — | −$4.44 | $0.03 | −$3.44 | — | $0.35 |